Symbiosis Pharma to manufacture Modus’ sepsis treatment
pharmafile | October 12, 2021 | News story | Manufacturing and Production |
Modus Therapeutics, a company developing pharmaceutical therapies for diseases with high unmet medical need, has announced that Symbiosis Pharmaceutical Services Ltd has begun manufacturing sevuparin. This secures the supply for the Phase II clinical development in sepsis, and other conditions driven by systematic inflammation.
The manufacturing of sevuparin follows a recent drug supply agreement between Modus and Symbiosis, covering the drug product needs for the Phase II programme.
Sevuparin is a clinical stage, innovative polysaccharide, with the potential to break the molecular chain of events that lead to vascular damage and plasma leakage in patients with sepsis/septic shock. The drug achieves this through directly binding and neutralising agents released from activated white blood cells that threaten vascular integrity.
John Öhd, CEO of Modus Therapeutics, commented on the collaboration: “Modus firmly believes there is an urgency to bring new improved medicines to this underserved field. Timely delivery of drug product is of utmost importance for us to be able to meet the aggressive timelines of our planned development.
“The manufacturing of this new batch of sevuparin is an important step in securing supply to our Phase II program in patients with sepsis, planned to start in Q3/Q4 2022. We believe Symbiosis Pharma’s strong track record makes them our ideal partner and we look forward to a productive and rewarding collaboration.”
Colin MacKay, founder and CEO of Symbiosis, added: “Our team is very proud to support Modus Therapeutics and its effort to develop a powerful treatment for sepsis/septic shock. With many years of direct experience manufacturing an array of medicines and vaccines for clinical trials and commercial markets, we are pleased to be able to support the accelerated clinical development of sevuparin and to add value and contribute to the successful achievements of Modus Therapeutics’ drug development milestones.”
Lina Adams
